CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Health Canada has approved the commercialization of INTERCEPT Blood System for platelets. The INTERCEPT Blood ...
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for ...
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq:CERS) announced today FDA regulatory approval for manufacture of INTERCEPT plasma with a new, alternative plastic disposable kit. The ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that investigators from blood centers in Sweden, Belgium, France and Slovenia will present their experience with the ...
CONCORD, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) and Grifols S.A. (MCE:GRF) today announced that the two companies have entered into an agreement extending Grifols’ ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS), a company solely dedicated to safeguarding the global blood supply, and the Transfusion Service of the Swiss Red Cross (Blutspende ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results